Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis
Objective To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. Methods Longitudinal, retrospective and multicentre study including patients with RA who were treated wit...
| Autores: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:304080 |
| Acceso en línea: | https://ddd.uab.cat/record/304080 https://dx.doi.org/urn:doi:10.1136/rmdopen-2023-003975 |
| Access Level: | acceso abierto |
| Palabra clave: | Antibodies, Monoclonal Arthritis, Rheumatoid Certolizumab Pegol Etanercept Humans Retrospective Studies Rheumatoid Factor Treatment Outcome Tumor Necrosis Factor Inhibitors |
| id |
ES_651cf59f940cbac6d5da4ccd79fcf2aa |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:304080 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritisa multicentre and retrospective studyLópez-Medina, Clementina|||0000-0002-2309-5837Calvo-Gutiérrez, JerusalemÁbalos-Aguilera, M. CarmenCepas, FranciscoPlasencia-Rodríguez, Chamaida|||0000-0003-3503-9047Martínez-Feito, Ana|||0000-0002-5580-8387Balsa, Alejandro|||0000-0001-8070-7062Faré-García, ReginaJuan-Mas, AntoniRuiz-Esquide, Virginia|||0000-0002-2657-6601Sainz, Luis|||0000-0001-9249-1983Diaz-Torne, Cesar|||0000-0001-6275-7699Godoy-Navarrete, Francisco JavierAñón-Oñate, IsabelMena-Vázquez, Natalia|||0000-0001-6173-2051Manrique-Arija, Sara|||0000-0003-2284-7846Moreno-García, Marina SoledadOrtega-Castro, RafaelaEscudero-Contreras, AlejandroAntibodies, MonoclonalArthritis, RheumatoidCertolizumab PegolEtanerceptHumansRetrospective StudiesRheumatoid FactorTreatment OutcomeTumor Necrosis Factor InhibitorsObjective To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. Methods Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions were conducted to evaluate the retention rate in the three groups according to the level of RF, with the third quartile of the baseline levels used as cutoff: <200 (<Q3) and ≥200 (≥Q3) IU/mL. A sensitivity analysis matching patients using a propensity score technique based on age, concomitant use of methotrexate and previous targeted synthetic/biological disease-modifying antirheumatic drugs was performed to address the imbalance across groups. Results A total of 638 individuals and 752 treatments (132 CZP, 439 mAB and 181 ETA) were included. In non-naïve patients with ≥200 IU/mL of RF, those treated with CZP showed a significantly longer retention rate in comparison with mAB and ETA. After matching using the propensity score, patients with ≥200 IU/mL RF levels exhibited longer retention rates with CZP than with mAB (HR 2.3 (95% CI 1.2 to 4.3), or ETA (HR 2.8 (95% CI 1.5 to 5.2). No differences were found between groups in patients with <200 UI/mL. Conclusions CZP showed a longer retention rate than mAB and ETA in patients with very high RF levels (≥200 IU/mL), while these differences were absent in patients with <200 IU/mL levels. The results suggest the potential effect of RF on binding the fragment crystallisable portion of certain TNFi. 22024-01-0120242024-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/304080https://dx.doi.org/urn:doi:10.1136/rmdopen-2023-003975reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3040802026-06-06T12:50:31Z |
| dc.title.none.fl_str_mv |
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis a multicentre and retrospective study |
| title |
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis |
| spellingShingle |
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis López-Medina, Clementina|||0000-0002-2309-5837 Antibodies, Monoclonal Arthritis, Rheumatoid Certolizumab Pegol Etanercept Humans Retrospective Studies Rheumatoid Factor Treatment Outcome Tumor Necrosis Factor Inhibitors |
| title_short |
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis |
| title_full |
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis |
| title_fullStr |
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis |
| title_full_unstemmed |
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis |
| title_sort |
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis |
| dc.creator.none.fl_str_mv |
López-Medina, Clementina|||0000-0002-2309-5837 Calvo-Gutiérrez, Jerusalem Ábalos-Aguilera, M. Carmen Cepas, Francisco Plasencia-Rodríguez, Chamaida|||0000-0003-3503-9047 Martínez-Feito, Ana|||0000-0002-5580-8387 Balsa, Alejandro|||0000-0001-8070-7062 Faré-García, Regina Juan-Mas, Antoni Ruiz-Esquide, Virginia|||0000-0002-2657-6601 Sainz, Luis|||0000-0001-9249-1983 Diaz-Torne, Cesar|||0000-0001-6275-7699 Godoy-Navarrete, Francisco Javier Añón-Oñate, Isabel Mena-Vázquez, Natalia|||0000-0001-6173-2051 Manrique-Arija, Sara|||0000-0003-2284-7846 Moreno-García, Marina Soledad Ortega-Castro, Rafaela Escudero-Contreras, Alejandro |
| author |
López-Medina, Clementina|||0000-0002-2309-5837 |
| author_facet |
López-Medina, Clementina|||0000-0002-2309-5837 Calvo-Gutiérrez, Jerusalem Ábalos-Aguilera, M. Carmen Cepas, Francisco Plasencia-Rodríguez, Chamaida|||0000-0003-3503-9047 Martínez-Feito, Ana|||0000-0002-5580-8387 Balsa, Alejandro|||0000-0001-8070-7062 Faré-García, Regina Juan-Mas, Antoni Ruiz-Esquide, Virginia|||0000-0002-2657-6601 Sainz, Luis|||0000-0001-9249-1983 Diaz-Torne, Cesar|||0000-0001-6275-7699 Godoy-Navarrete, Francisco Javier Añón-Oñate, Isabel Mena-Vázquez, Natalia|||0000-0001-6173-2051 Manrique-Arija, Sara|||0000-0003-2284-7846 Moreno-García, Marina Soledad Ortega-Castro, Rafaela Escudero-Contreras, Alejandro |
| author_role |
author |
| author2 |
Calvo-Gutiérrez, Jerusalem Ábalos-Aguilera, M. Carmen Cepas, Francisco Plasencia-Rodríguez, Chamaida|||0000-0003-3503-9047 Martínez-Feito, Ana|||0000-0002-5580-8387 Balsa, Alejandro|||0000-0001-8070-7062 Faré-García, Regina Juan-Mas, Antoni Ruiz-Esquide, Virginia|||0000-0002-2657-6601 Sainz, Luis|||0000-0001-9249-1983 Diaz-Torne, Cesar|||0000-0001-6275-7699 Godoy-Navarrete, Francisco Javier Añón-Oñate, Isabel Mena-Vázquez, Natalia|||0000-0001-6173-2051 Manrique-Arija, Sara|||0000-0003-2284-7846 Moreno-García, Marina Soledad Ortega-Castro, Rafaela Escudero-Contreras, Alejandro |
| author2_role |
author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Antibodies, Monoclonal Arthritis, Rheumatoid Certolizumab Pegol Etanercept Humans Retrospective Studies Rheumatoid Factor Treatment Outcome Tumor Necrosis Factor Inhibitors |
| topic |
Antibodies, Monoclonal Arthritis, Rheumatoid Certolizumab Pegol Etanercept Humans Retrospective Studies Rheumatoid Factor Treatment Outcome Tumor Necrosis Factor Inhibitors |
| description |
Objective To assess whether the retention rate of certolizumab pegol (CZP) was longer than that of other tumour necrosis factor inhibitors (TNFi) based on baseline rheumatoid factor (RF) levels. Methods Longitudinal, retrospective and multicentre study including patients with RA who were treated with any TNFi (monoclonal antibodies (mAB), etanercept (ETA) or CZP). Log-rank test and Cox regressions were conducted to evaluate the retention rate in the three groups according to the level of RF, with the third quartile of the baseline levels used as cutoff: <200 (<Q3) and ≥200 (≥Q3) IU/mL. A sensitivity analysis matching patients using a propensity score technique based on age, concomitant use of methotrexate and previous targeted synthetic/biological disease-modifying antirheumatic drugs was performed to address the imbalance across groups. Results A total of 638 individuals and 752 treatments (132 CZP, 439 mAB and 181 ETA) were included. In non-naïve patients with ≥200 IU/mL of RF, those treated with CZP showed a significantly longer retention rate in comparison with mAB and ETA. After matching using the propensity score, patients with ≥200 IU/mL RF levels exhibited longer retention rates with CZP than with mAB (HR 2.3 (95% CI 1.2 to 4.3), or ETA (HR 2.8 (95% CI 1.5 to 5.2). No differences were found between groups in patients with <200 UI/mL. Conclusions CZP showed a longer retention rate than mAB and ETA in patients with very high RF levels (≥200 IU/mL), while these differences were absent in patients with <200 IU/mL levels. The results suggest the potential effect of RF on binding the fragment crystallisable portion of certain TNFi. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2 2024-01-01 2024 2024-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/304080 https://dx.doi.org/urn:doi:10.1136/rmdopen-2023-003975 |
| url |
https://ddd.uab.cat/record/304080 https://dx.doi.org/urn:doi:10.1136/rmdopen-2023-003975 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869409718149054464 |
| score |
15,811543 |